MarketInOut Stock Screener Log In | Sign Up
 

Nkarta Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Nkarta Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization127.85 mln
Float57.57 mln
Earnings Date11/11/2026

Piotroski F-Score

1 / 9
Very weak

Relative Strength

12 / 100
Significantly lagging

Debt / Equity

0.30
Low leverage

ROE

-38.06
Deeply negative

ROA

-29.29
Deeply negative

Business Description

Nkarta is a South San Francisco-based medical company focused on developing treatments that use natural killer cells to fight cancer and autoimmune conditions. Its main therapy, NKX019, is currently being tested in early-stage clinical trials for several serious immune disorders, including lupus and related conditions. Founded in 2015, the company works alongside CRISPR Therapeutics to advance its research.

Key Fundamentals

EPS-1.58
ROE-38.06
ROIC-91.16
ROA-29.29
EBITDA, mln-108
EV / EBITDA-0.80
EV / EBIT-0.74

Quote Details

Last 1.79
Change 0.05 (2.87%)
Open 1.74
Volume 959,153
Turnover 1,716,884
Average Volume 863,667

Financial Ratios

Leverage Ratio1.36
Current Ratio7.98
Price / Book0.76
Price / Tangible Book0.76
Debt / Equity0.30

Financial Strength

Piotroski F-Score 1 / 9
Short Ratio5.80
Short % of Float6.39

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.56% 40 / 100   
1 Month -37.19% 8 / 100   
2 Months -30.35% 16 / 100   
6 Months -38.7% 17 / 100   
1 Year -18.64% 31 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog